MedTrace Logo

FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer

NCT00983697 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2020-10-23

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET/CT scan, may help doctors find head and neck cancer and find out how far the disease has spread. It may also help doctors plan the best treatment.

PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing the tumor and planning neck surgery in patients with newly diagnosed head and neck cancer.

Conditions

Interventions

PROCEDURE

therapeutic conventional surgery

RADIATION

fludeoxyglucose F 18

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • American College of Radiology Imaging Network

    lead NETWORK

Principal Investigators

  • Val J. Lowe, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-01
Primary Completion
2019-01-15
Completion
2021-12-31

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00983697 on ClinicalTrials.gov